🟢 Eli Lilly is trading 3.06% up today after FDA approval of once-weekly Onswik insulin

Eli Lilly is trading 3.06% up at $1,186.24 after FDA approval of Onswik, its once-weekly basal insulin for adults with type 2 diabetes.

• Onswik offers an alternative to daily long-acting insulin and will launch in the United States in coming months.
• Major market indexes are lower on September 24, 2026.
• Home Depot co-founder Ken Langone said Eli Lilly could reach $2,000 in three to four years; FDA approval is the more direct catalyst.